Skip to content
HowShorted

MYRIAD GENETICS INC short interest in 2020

In 2020, MYRIAD GENETICS INC's disclosed short interest ran from 17.23% of shares outstanding on 15 Jan 2020 to 12.09% on 31 Dec 2020, a change of -5.14 percentage points. The year's high was 17.23% on 15 Jan 2020 and its low 9.92% on 15 May 2020, averaging 13.63% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 22.16 days on 15 Jan 2020. Full history: MYRIAD GENETICS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for MYRIAD GENETICS INC in 2020

2020 in figures

Start of year
17.23% (15 Jan 2020)
End of year
12.09% (31 Dec 2020)
Change
-5.14 pp
High
17.23% (15 Jan 2020)
Low
9.92% (15 May 2020)
Average
13.63%
Highest days to cover
22.16 (15 Jan 2020)
SEC filings marked
8

Every report in 2020

MYRIAD GENETICS INC short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202017.23%22.16
31 Jan 202015.83%21.87
14 Feb 202017.13%6.67results (8-K), 10-Q filed
28 Feb 202016.98%13.43
13 Mar 202015.79%10.52
31 Mar 202012.40%7.86
15 Apr 202012.62%12.37
30 Apr 202011.74%11.36
15 May 20209.92%6.16results (8-K), 10-Q filed
29 May 20209.94%9.53
15 Jun 202011.96%5.26
30 Jun 202014.65%7.56
15 Jul 202014.75%13.49
31 Jul 202014.54%18.19
14 Aug 202014.29%18.2910-K filed, results (8-K)
31 Aug 202014.36%12.17
15 Sep 202014.10%16.48
30 Sep 202012.56%14.96
15 Oct 202012.33%20.39
30 Oct 202012.77%19.61
13 Nov 202013.17%14.1610-Q filed, results (8-K)
30 Nov 202013.00%20.32
15 Dec 202012.86%12.91
31 Dec 202012.09%12.02

See also: MYRIAD GENETICS INC's full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.